Searched for
DIPP DG SHAH
Companies oppose extension of new drug validity periodAs per current provisions, an application for a ‘new drug’ is approved only by the central drug regulatory agency for four years.- Government approves new IPR policy; India Inc hails move while pharma firms wary about changesThe government has approved a new IPR policy that seeks to encourage innovation and improve access to healthcare, food security and environ...
- Foreign drug makers urge government to review IPR think tankA similar point has also been raised by the US biotech groupings PhRMA and BIO in their submissions to the US Trade Representative's office.
- Pharma companies feel law change can weaken ability to provide low-cost drugsIndian drugmakers are also concerned about a shift in India’s position on IPR, which they say is being keenly watched by many developing co...
- DIPP for extending provision of Compulsory Licences beyond cancer drugsThe move will drastically reduce prices of key drugs, but at the same time, jeopardise the plans of multinational drug companies.
- Pharma FDI checks to shield local companiesA discussion paper put up for consultation by DIPP suggests that the drugs industry may be taken off the list of sectors where FDI is allow...
Load More